Healthcare Conference

Mar 06, 2024

Major Highlights and Insights from the AAAAI Annual Meeting, 2024

Dec 12, 2023

Liso-cel in TRANSCEND CLL 004: Unprecedented and Sustained Responses with Manageable Safety Profile, Signaling a Promising Advance in Relapsed or Refractory CLL Treatment

Dec 08, 2023

Unlocking the Future of Hematology: A Sneak Peek into ASH 2023 Discoveries!

Apr 14, 2023

American Association for Cancer Research (AACR) 2023 Preview – Top Data Readouts

Dec 19, 2022

ASH 2022- Emergence of Bispecific antibodies in DLBCL: Prospects, Opportunities, and Challenges

Dec 19, 2022

ASH 2022: Preview of the Top Abstracts In the Follicular Lymphoma (FL) Therapeutics Market

Dec 16, 2022

ASH 2022: Roche’s Polivy vs ADC Therapeutics’ Zynlonta, Antibody-Drug Conjugates (ADC) in R/R DLBCL

Dec 23, 2021

Major Highlights of Diffuse Large B-cell Lymphoma/ Large B-cell lymphoma (LBCL) in ASH 2021

Dec 23, 2021

Major Highlights of Follicular Lymphoma (FL) in ASH 2021

Dec 13, 2021

Myelodysplastic Syndromes (MDS): Key Pharma Players Unveiling Updated Findings at ASH 2021

Newsletter/Whitepaper